Consolidated Statements of Cash Flows - USD ($) $ in Thousands	12 Months Ended		60 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2015
Cash flows from operating activities:
Net loss	$ (52,188)	$ (41,844)	$ (138,759)
Adjustments to reconcile net loss to net cash used in operating activities:
Gain on sale of subsidiary	(1,016)
Gain on the change in contingent consideration	(409)
Depreciation and amortization	597	165
Non-cash interest expense	373	2,475
Non-cash accretion expense	170
Deferred taxes	(608)	(185)
Stock-based compensation and vesting of restricted stock	3,470	1,719
Other receivable recovery	(177)
Deferred rent and lease incentive activity	(43)	95
Loss on disposal of equipment	1
Loss on impairment of asset held for sale	1,671
Extinguishment of convertible notes		(22)
Change in fair value of warrants		222
Changes in operating assets and liabilities:
Prepaid expenses and other current assets	(1,982)	(276)
Restricted cash	(99)	50
Other non-current assets	111	(304)
Accounts payable	(1,235)	(174)
Accrued expenses and other current liabilities	3,302	1,823
Other non-current liabilities	(196)	(210)
Deferred revenue	698	996
Settlement obligation	978
Net cash used in operating activities	(46,582)	(35,470)
Cash flows from investing activities:
Cash acquired in acquisition	889	13,756
Payment to stockholders of Bioceros	(3,400)
Proceeds from the sale of In process research and development	3,829
Additions to intangible assets		(1,250)
Proceeds from the sale of property & equipment		4
Purchases of property and equipment	(477)	(217)
Net cash provided by investing activities	841	12,293
Cash flows from financing activities
Proceeds from the issuance of common stock, net of costs	47,962
Proceeds from the issuance of preferred stock and warrants		30,478
Proceeds from the issuance of convertible notes		5,000
Proceeds from the issuance of debt, net of fees paid to lender	7,500	7,285
Payment of debt issuance costs		(49)
Proceeds from the exercise of preferred stock warrants		334
Repurchases of common stock		(297)
Proceeds from the exercise of common stock options	355	90
Net cash provided by financing activities	55,817	42,841
Effect of exchange rate changes on cash and cash equivalents	(23)
Net increase (decrease) in cash and cash equivalents	10,053	19,664
Cash and cash equivalents - Beginning of period	21,462	1,798
Cash and cash equivalents - End of period	31,515	21,462	31,515
Supplemental disclosure of cash flow information
Cash paid for interest	913	101
Cash paid for income taxes	40	177
Supplemental schedule of non-cash investing and financing activities:
Amounts in accounts payable for capital expenditure	657	5	$ 657
Conversion of convertible debt and accrued interest into preferred stock and warrants		13,184
Extinguishment of convertible debt and accrued interest into preferred stock		5,013
Exercise of warrants into preferred stock		7,095
Conversion of preferred stock into common stock		79,452
Conversion of preferred stock warrants to equity		167
Issuance of warrants in connection with Hercules debt		248
Leasehold improvements incurred by landlord		477
Fair value of assets and liabilities acquired in the Acquisition (Note 6):
Fair value of assets acquired in the Acquisition	15,697
Fair value of liabilities assumed in the Acquisition	(2,084)
Fair value of net assets acquired in the Acquisition	$ 13,613
Fair value of assets and liabilities acquired in the Merger (Note 5):
Fair value of assets acquired in the Merger		36,223
Fair value of liabilities assumed in the Merger		(4,899)
Fair value of net assets acquired in the Merger		$ 31,324